Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Key facts
- Where
- Bordeaux, Lille, Lyon, Paris, Saint-Cloud, and Vandœuvre-lès-Nancy, FranceSee the 6 sites
Where in France
- Institut BergonieBordeaux, FranceTaking people
- Centre Oscar LambretLille, FranceTaking people
- Centre Leon BerardLyon, FranceTaking people
- Institut CurieParis, FranceTaking people
- Institut Curie - Hôpital René HugueninSaint-Cloud, FranceTaking people
- Institut de Cancérologie de Lorraine - NancyVandœuvre-lès-Nancy, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut Curie
- Trial code
- NCT03017573
- Record updated
- 3 February 2026
- Original description
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.Read full original descriptionShow less
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.
Inclusion: Tumor types :; Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy; Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy; Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery; Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancer patients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2); Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma or (2) uterine sarcoma eligible for surgery or systemic treatment; Male or female patients ≥ 18 years of age; Signed informed consent.
Exclusion: Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; Male or female patients ≤18 years old; Individually deprived of liberty or placed under the authority of a tutor; Patients not affiliated to the Social Security System.